髄膜炎菌多糖類ワクチンのグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Meningococcal Polysaccharide Vaccine Market Insights, Forecast to 2028

• レポートコード：QY2207E10407 • 出版社/出版日：QYResearch / 2022年7月 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥735,000 (USD4,900)	▷ お問い合わせ
Multi User	￥1,102,500 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,470,000 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

新型コロナウイルス感染症のパンデミックにより、世界の髄膜炎菌多糖類ワクチンの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に髄膜炎菌多糖類ワクチンの世界市場のxxx％を占める「多糖類髄膜炎AC」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「6ヶ月-15年」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の髄膜炎菌多糖類ワクチンの市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの髄膜炎菌多糖類ワクチン市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの髄膜炎菌多糖類ワクチン市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 髄膜炎菌多糖類ワクチンのグローバル主要メーカーには、Sanofi、Bio-Med、CanSinoBIO、Walvax Biotechnology、Chongqing Zhifei Biological、Chengdu Kanghua Biological Products、Changsheng Biotechnology、CanSinoBIOなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 髄膜炎菌多糖類ワクチン市場は、種類と用途によって区分されます。世界の髄膜炎菌多糖類ワクチン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 多糖類髄膜炎AC、髄膜炎ACYW 【用途別セグメント】 6ヶ月-15年、3年以上、2年以上、3ヶ月以上 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 髄膜炎菌多糖類ワクチン製品概要 - 種類別市場（多糖類髄膜炎AC、髄膜炎ACYW） - 用途別市場（6ヶ月-15年、3年以上、2年以上、3ヶ月以上） - 調査の目的 ・エグゼクティブサマリー - 世界の髄膜炎菌多糖類ワクチン販売量予測2017-2028 - 世界の髄膜炎菌多糖類ワクチン売上予測2017-2028 - 髄膜炎菌多糖類ワクチンの地域別販売量 - 髄膜炎菌多糖類ワクチンの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別髄膜炎菌多糖類ワクチン販売量 - 主要メーカー別髄膜炎菌多糖類ワクチン売上 - 主要メーカー別髄膜炎菌多糖類ワクチン価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（多糖類髄膜炎AC、髄膜炎ACYW） - 髄膜炎菌多糖類ワクチンの種類別販売量 - 髄膜炎菌多糖類ワクチンの種類別売上 - 髄膜炎菌多糖類ワクチンの種類別価格 ・用途別市場規模（6ヶ月-15年、3年以上、2年以上、3ヶ月以上） - 髄膜炎菌多糖類ワクチンの用途別販売量 - 髄膜炎菌多糖類ワクチンの用途別売上 - 髄膜炎菌多糖類ワクチンの用途別価格 ・北米市場 - 北米の髄膜炎菌多糖類ワクチン市場規模（種類別、用途別） - 主要国別の髄膜炎菌多糖類ワクチン市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの髄膜炎菌多糖類ワクチン市場規模（種類別、用途別） - 主要国別の髄膜炎菌多糖類ワクチン市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の髄膜炎菌多糖類ワクチン市場規模（種類別、用途別） - 主要国別の髄膜炎菌多糖類ワクチン市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の髄膜炎菌多糖類ワクチン市場規模（種類別、用途別） - 主要国別の髄膜炎菌多糖類ワクチン市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの髄膜炎菌多糖類ワクチン市場規模（種類別、用途別） - 主要国別の髄膜炎菌多糖類ワクチン市場規模（トルコ、サウジアラビア） ・企業情報 Sanofi、Bio-Med、CanSinoBIO、Walvax Biotechnology、Chongqing Zhifei Biological、Chengdu Kanghua Biological Products、Changsheng Biotechnology、CanSinoBIO ・産業チェーン及び販売チャネル分析 - 髄膜炎菌多糖類ワクチンの産業チェーン分析 - 髄膜炎菌多糖類ワクチンの原材料 - 髄膜炎菌多糖類ワクチンの生産プロセス - 髄膜炎菌多糖類ワクチンの販売及びマーケティング - 髄膜炎菌多糖類ワクチンの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 髄膜炎菌多糖類ワクチンの産業動向 - 髄膜炎菌多糖類ワクチンのマーケットドライバー - 髄膜炎菌多糖類ワクチンの課題 - 髄膜炎菌多糖類ワクチンの阻害要因 ・主な調査結果

Meningococcal polysaccharide diphtheria conjugate vaccine is an active immunizing agent used to prevent infection by certain groups of meningococcal bacteria.
Market Analysis and Insights: Global Meningococcal Polysaccharide Vaccine Market
Due to the COVID-19 pandemic, the global Meningococcal Polysaccharide Vaccine market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Polysaccharide Meningtitis AC accounting for % of the Meningococcal Polysaccharide Vaccine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While 6 Months-15Year segment is altered to an % CAGR throughout this forecast period.
China Meningococcal Polysaccharide Vaccine market size is valued at US$ million in 2021, while the US and Europe Meningococcal Polysaccharide Vaccine are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Meningococcal Polysaccharide Vaccine landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Meningococcal Polysaccharide Vaccine include Sanofi, Bio-Med, CanSinoBIO, Walvax Biotechnology, Chongqing Zhifei Biological, Chengdu Kanghua Biological Products, Changsheng Biotechnology and CanSinoBIO, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Meningococcal Polysaccharide Vaccine Scope and Segment
Meningococcal Polysaccharide Vaccine market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Meningococcal Polysaccharide Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Polysaccharide Meningtitis AC
Meningitis ACYW
Segment by Application
6 Months-15Year
over 3 Year
over 2 Year
over 3 Months
By Company
Sanofi
Bio-Med
CanSinoBIO
Walvax Biotechnology
Chongqing Zhifei Biological
Chengdu Kanghua Biological Products
Changsheng Biotechnology
CanSinoBIO
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

---

1 Study Coverage
1.1 Meningococcal Polysaccharide Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Meningococcal Polysaccharide Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Polysaccharide Meningtitis AC
1.2.3 Meningitis ACYW
1.3 Market by Application
1.3.1 Global Meningococcal Polysaccharide Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 6 Months-15Year
1.3.3 over 3 Year
1.3.4 over 2 Year
1.3.5 over 3 Months
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Meningococcal Polysaccharide Vaccine Sales Estimates and Forecasts 2017-2028
2.2 Global Meningococcal Polysaccharide Vaccine Revenue Estimates and Forecasts 2017-2028
2.3 Global Meningococcal Polysaccharide Vaccine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Meningococcal Polysaccharide Vaccine Sales by Region
2.4.1 Global Meningococcal Polysaccharide Vaccine Sales by Region (2017-2022)
2.4.2 Global Sales Meningococcal Polysaccharide Vaccine by Region (2023-2028)
2.5 Global Meningococcal Polysaccharide Vaccine Revenue by Region
2.5.1 Global Meningococcal Polysaccharide Vaccine Revenue by Region (2017-2022)
2.5.2 Global Meningococcal Polysaccharide Vaccine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Meningococcal Polysaccharide Vaccine Sales by Manufacturers
3.1.1 Global Top Meningococcal Polysaccharide Vaccine Manufacturers by Sales (2017-2022)
3.1.2 Global Meningococcal Polysaccharide Vaccine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Meningococcal Polysaccharide Vaccine in 2021
3.2 Global Meningococcal Polysaccharide Vaccine Revenue by Manufacturers
3.2.1 Global Meningococcal Polysaccharide Vaccine Revenue by Manufacturers (2017-2022)
3.2.2 Global Meningococcal Polysaccharide Vaccine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Meningococcal Polysaccharide Vaccine Revenue in 2021
3.3 Global Meningococcal Polysaccharide Vaccine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Meningococcal Polysaccharide Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Meningococcal Polysaccharide Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Meningococcal Polysaccharide Vaccine Sales by Type
4.1.1 Global Meningococcal Polysaccharide Vaccine Historical Sales by Type (2017-2022)
4.1.2 Global Meningococcal Polysaccharide Vaccine Forecasted Sales by Type (2023-2028)
4.1.3 Global Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2017-2028)
4.2 Global Meningococcal Polysaccharide Vaccine Revenue by Type
4.2.1 Global Meningococcal Polysaccharide Vaccine Historical Revenue by Type (2017-2022)
4.2.2 Global Meningococcal Polysaccharide Vaccine Forecasted Revenue by Type (2023-2028)
4.2.3 Global Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2017-2028)
4.3 Global Meningococcal Polysaccharide Vaccine Price by Type
4.3.1 Global Meningococcal Polysaccharide Vaccine Price by Type (2017-2022)
4.3.2 Global Meningococcal Polysaccharide Vaccine Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Meningococcal Polysaccharide Vaccine Sales by Application
5.1.1 Global Meningococcal Polysaccharide Vaccine Historical Sales by Application (2017-2022)
5.1.2 Global Meningococcal Polysaccharide Vaccine Forecasted Sales by Application (2023-2028)
5.1.3 Global Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2017-2028)
5.2 Global Meningococcal Polysaccharide Vaccine Revenue by Application
5.2.1 Global Meningococcal Polysaccharide Vaccine Historical Revenue by Application (2017-2022)
5.2.2 Global Meningococcal Polysaccharide Vaccine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2017-2028)
5.3 Global Meningococcal Polysaccharide Vaccine Price by Application
5.3.1 Global Meningococcal Polysaccharide Vaccine Price by Application (2017-2022)
5.3.2 Global Meningococcal Polysaccharide Vaccine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Meningococcal Polysaccharide Vaccine Market Size by Type
6.1.1 North America Meningococcal Polysaccharide Vaccine Sales by Type (2017-2028)
6.1.2 North America Meningococcal Polysaccharide Vaccine Revenue by Type (2017-2028)
6.2 North America Meningococcal Polysaccharide Vaccine Market Size by Application
6.2.1 North America Meningococcal Polysaccharide Vaccine Sales by Application (2017-2028)
6.2.2 North America Meningococcal Polysaccharide Vaccine Revenue by Application (2017-2028)
6.3 North America Meningococcal Polysaccharide Vaccine Market Size by Country
6.3.1 North America Meningococcal Polysaccharide Vaccine Sales by Country (2017-2028)
6.3.2 North America Meningococcal Polysaccharide Vaccine Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Meningococcal Polysaccharide Vaccine Market Size by Type
7.1.1 Europe Meningococcal Polysaccharide Vaccine Sales by Type (2017-2028)
7.1.2 Europe Meningococcal Polysaccharide Vaccine Revenue by Type (2017-2028)
7.2 Europe Meningococcal Polysaccharide Vaccine Market Size by Application
7.2.1 Europe Meningococcal Polysaccharide Vaccine Sales by Application (2017-2028)
7.2.2 Europe Meningococcal Polysaccharide Vaccine Revenue by Application (2017-2028)
7.3 Europe Meningococcal Polysaccharide Vaccine Market Size by Country
7.3.1 Europe Meningococcal Polysaccharide Vaccine Sales by Country (2017-2028)
7.3.2 Europe Meningococcal Polysaccharide Vaccine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Meningococcal Polysaccharide Vaccine Market Size by Type
8.1.1 Asia Pacific Meningococcal Polysaccharide Vaccine Sales by Type (2017-2028)
8.1.2 Asia Pacific Meningococcal Polysaccharide Vaccine Revenue by Type (2017-2028)
8.2 Asia Pacific Meningococcal Polysaccharide Vaccine Market Size by Application
8.2.1 Asia Pacific Meningococcal Polysaccharide Vaccine Sales by Application (2017-2028)
8.2.2 Asia Pacific Meningococcal Polysaccharide Vaccine Revenue by Application (2017-2028)
8.3 Asia Pacific Meningococcal Polysaccharide Vaccine Market Size by Region
8.3.1 Asia Pacific Meningococcal Polysaccharide Vaccine Sales by Region (2017-2028)
8.3.2 Asia Pacific Meningococcal Polysaccharide Vaccine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Meningococcal Polysaccharide Vaccine Market Size by Type
9.1.1 Latin America Meningococcal Polysaccharide Vaccine Sales by Type (2017-2028)
9.1.2 Latin America Meningococcal Polysaccharide Vaccine Revenue by Type (2017-2028)
9.2 Latin America Meningococcal Polysaccharide Vaccine Market Size by Application
9.2.1 Latin America Meningococcal Polysaccharide Vaccine Sales by Application (2017-2028)
9.2.2 Latin America Meningococcal Polysaccharide Vaccine Revenue by Application (2017-2028)
9.3 Latin America Meningococcal Polysaccharide Vaccine Market Size by Country
9.3.1 Latin America Meningococcal Polysaccharide Vaccine Sales by Country (2017-2028)
9.3.2 Latin America Meningococcal Polysaccharide Vaccine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Meningococcal Polysaccharide Vaccine Market Size by Type
10.1.1 Middle East and Africa Meningococcal Polysaccharide Vaccine Sales by Type (2017-2028)
10.1.2 Middle East and Africa Meningococcal Polysaccharide Vaccine Revenue by Type (2017-2028)
10.2 Middle East and Africa Meningococcal Polysaccharide Vaccine Market Size by Application
10.2.1 Middle East and Africa Meningococcal Polysaccharide Vaccine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Meningococcal Polysaccharide Vaccine Revenue by Application (2017-2028)
10.3 Middle East and Africa Meningococcal Polysaccharide Vaccine Market Size by Country
10.3.1 Middle East and Africa Meningococcal Polysaccharide Vaccine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Meningococcal Polysaccharide Vaccine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Sanofi
11.1.1 Sanofi Corporation Information
11.1.2 Sanofi Overview
11.1.3 Sanofi Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Sanofi Meningococcal Polysaccharide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Sanofi Recent Developments
11.2 Bio-Med
11.2.1 Bio-Med Corporation Information
11.2.2 Bio-Med Overview
11.2.3 Bio-Med Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Bio-Med Meningococcal Polysaccharide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Bio-Med Recent Developments
11.3 CanSinoBIO
11.3.1 CanSinoBIO Corporation Information
11.3.2 CanSinoBIO Overview
11.3.3 CanSinoBIO Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 CanSinoBIO Meningococcal Polysaccharide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 CanSinoBIO Recent Developments
11.4 Walvax Biotechnology
11.4.1 Walvax Biotechnology Corporation Information
11.4.2 Walvax Biotechnology Overview
11.4.3 Walvax Biotechnology Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Walvax Biotechnology Meningococcal Polysaccharide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Walvax Biotechnology Recent Developments
11.5 Chongqing Zhifei Biological
11.5.1 Chongqing Zhifei Biological Corporation Information
11.5.2 Chongqing Zhifei Biological Overview
11.5.3 Chongqing Zhifei Biological Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Chongqing Zhifei Biological Meningococcal Polysaccharide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Chongqing Zhifei Biological Recent Developments
11.6 Chengdu Kanghua Biological Products
11.6.1 Chengdu Kanghua Biological Products Corporation Information
11.6.2 Chengdu Kanghua Biological Products Overview
11.6.3 Chengdu Kanghua Biological Products Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Chengdu Kanghua Biological Products Meningococcal Polysaccharide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Chengdu Kanghua Biological Products Recent Developments
11.7 Changsheng Biotechnology
11.7.1 Changsheng Biotechnology Corporation Information
11.7.2 Changsheng Biotechnology Overview
11.7.3 Changsheng Biotechnology Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Changsheng Biotechnology Meningococcal Polysaccharide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Changsheng Biotechnology Recent Developments
11.8 CanSinoBIO
11.8.1 CanSinoBIO Corporation Information
11.8.2 CanSinoBIO Overview
11.8.3 CanSinoBIO Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 CanSinoBIO Meningococcal Polysaccharide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 CanSinoBIO Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Meningococcal Polysaccharide Vaccine Industry Chain Analysis
12.2 Meningococcal Polysaccharide Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Meningococcal Polysaccharide Vaccine Production Mode & Process
12.4 Meningococcal Polysaccharide Vaccine Sales and Marketing
12.4.1 Meningococcal Polysaccharide Vaccine Sales Channels
12.4.2 Meningococcal Polysaccharide Vaccine Distributors
12.5 Meningococcal Polysaccharide Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Meningococcal Polysaccharide Vaccine Industry Trends
13.2 Meningococcal Polysaccharide Vaccine Market Drivers
13.3 Meningococcal Polysaccharide Vaccine Market Challenges
13.4 Meningococcal Polysaccharide Vaccine Market Restraints
14 Key Findings in The Global Meningococcal Polysaccharide Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Meningococcal Polysaccharide Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Polysaccharide Meningtitis AC
Table 3. Major Manufacturers of Meningitis ACYW
Table 4. Global Meningococcal Polysaccharide Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 5. Global Meningococcal Polysaccharide Vaccine Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Meningococcal Polysaccharide Vaccine Sales by Region (2017-2022) & (K Doses)
Table 7. Global Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2017-2022)
Table 8. Global Meningococcal Polysaccharide Vaccine Sales by Region (2023-2028) & (K Doses)
Table 9. Global Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2023-2028)
Table 10. Global Meningococcal Polysaccharide Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 11. Global Meningococcal Polysaccharide Vaccine Revenue Market Share by Region (2017-2022)
Table 12. Global Meningococcal Polysaccharide Vaccine Revenue by Region (2023-2028) & (US$ Million)
Table 13. Global Meningococcal Polysaccharide Vaccine Revenue Market Share by Region (2023-2028)
Table 14. Global Meningococcal Polysaccharide Vaccine Sales by Manufacturers (2017-2022) & (K Doses)
Table 15. Global Meningococcal Polysaccharide Vaccine Sales Share by Manufacturers (2017-2022)
Table 16. Global Meningococcal Polysaccharide Vaccine Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 17. Global Meningococcal Polysaccharide Vaccine Revenue Share by Manufacturers (2017-2022)
Table 18. Meningococcal Polysaccharide Vaccine Price by Manufacturers (2017-2022) &(US$/Dose)
Table 19. Global Meningococcal Polysaccharide Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 20. Global Meningococcal Polysaccharide Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Meningococcal Polysaccharide Vaccine as of 2021)
Table 21. Meningococcal Polysaccharide Vaccine Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Meningococcal Polysaccharide Vaccine Product Offered
Table 23. Date of Manufacturers Enter into Meningococcal Polysaccharide Vaccine Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Meningococcal Polysaccharide Vaccine Sales by Type (2017-2022) & (K Doses)
Table 26. Global Meningococcal Polysaccharide Vaccine Sales by Type (2023-2028) & (K Doses)
Table 27. Global Meningococcal Polysaccharide Vaccine Sales Share by Type (2017-2022)
Table 28. Global Meningococcal Polysaccharide Vaccine Sales Share by Type (2023-2028)
Table 29. Global Meningococcal Polysaccharide Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 30. Global Meningococcal Polysaccharide Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 31. Global Meningococcal Polysaccharide Vaccine Revenue Share by Type (2017-2022)
Table 32. Global Meningococcal Polysaccharide Vaccine Revenue Share by Type (2023-2028)
Table 33. Meningococcal Polysaccharide Vaccine Price by Type (2017-2022) & (US$/Dose)
Table 34. Global Meningococcal Polysaccharide Vaccine Price Forecast by Type (2023-2028) & (US$/Dose)
Table 35. Global Meningococcal Polysaccharide Vaccine Sales by Application (2017-2022) & (K Doses)
Table 36. Global Meningococcal Polysaccharide Vaccine Sales by Application (2023-2028) & (K Doses)
Table 37. Global Meningococcal Polysaccharide Vaccine Sales Share by Application (2017-2022)
Table 38. Global Meningococcal Polysaccharide Vaccine Sales Share by Application (2023-2028)
Table 39. Global Meningococcal Polysaccharide Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 40. Global Meningococcal Polysaccharide Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 41. Global Meningococcal Polysaccharide Vaccine Revenue Share by Application (2017-2022)
Table 42. Global Meningococcal Polysaccharide Vaccine Revenue Share by Application (2023-2028)
Table 43. Meningococcal Polysaccharide Vaccine Price by Application (2017-2022) & (US$/Dose)
Table 44. Global Meningococcal Polysaccharide Vaccine Price Forecast by Application (2023-2028) & (US$/Dose)
Table 45. North America Meningococcal Polysaccharide Vaccine Sales by Type (2017-2022) & (K Doses)
Table 46. North America Meningococcal Polysaccharide Vaccine Sales by Type (2023-2028) & (K Doses)
Table 47. North America Meningococcal Polysaccharide Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 48. North America Meningococcal Polysaccharide Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 49. North America Meningococcal Polysaccharide Vaccine Sales by Application (2017-2022) & (K Doses)
Table 50. North America Meningococcal Polysaccharide Vaccine Sales by Application (2023-2028) & (K Doses)
Table 51. North America Meningococcal Polysaccharide Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 52. North America Meningococcal Polysaccharide Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 53. North America Meningococcal Polysaccharide Vaccine Sales by Country (2017-2022) & (K Doses)
Table 54. North America Meningococcal Polysaccharide Vaccine Sales by Country (2023-2028) & (K Doses)
Table 55. North America Meningococcal Polysaccharide Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 56. North America Meningococcal Polysaccharide Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 57. Europe Meningococcal Polysaccharide Vaccine Sales by Type (2017-2022) & (K Doses)
Table 58. Europe Meningococcal Polysaccharide Vaccine Sales by Type (2023-2028) & (K Doses)
Table 59. Europe Meningococcal Polysaccharide Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 60. Europe Meningococcal Polysaccharide Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 61. Europe Meningococcal Polysaccharide Vaccine Sales by Application (2017-2022) & (K Doses)
Table 62. Europe Meningococcal Polysaccharide Vaccine Sales by Application (2023-2028) & (K Doses)
Table 63. Europe Meningococcal Polysaccharide Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 64. Europe Meningococcal Polysaccharide Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 65. Europe Meningococcal Polysaccharide Vaccine Sales by Country (2017-2022) & (K Doses)
Table 66. Europe Meningococcal Polysaccharide Vaccine Sales by Country (2023-2028) & (K Doses)
Table 67. Europe Meningococcal Polysaccharide Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 68. Europe Meningococcal Polysaccharide Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 69. Asia Pacific Meningococcal Polysaccharide Vaccine Sales by Type (2017-2022) & (K Doses)
Table 70. Asia Pacific Meningococcal Polysaccharide Vaccine Sales by Type (2023-2028) & (K Doses)
Table 71. Asia Pacific Meningococcal Polysaccharide Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 72. Asia Pacific Meningococcal Polysaccharide Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 73. Asia Pacific Meningococcal Polysaccharide Vaccine Sales by Application (2017-2022) & (K Doses)
Table 74. Asia Pacific Meningococcal Polysaccharide Vaccine Sales by Application (2023-2028) & (K Doses)
Table 75. Asia Pacific Meningococcal Polysaccharide Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 76. Asia Pacific Meningococcal Polysaccharide Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 77. Asia Pacific Meningococcal Polysaccharide Vaccine Sales by Region (2017-2022) & (K Doses)
Table 78. Asia Pacific Meningococcal Polysaccharide Vaccine Sales by Region (2023-2028) & (K Doses)
Table 79. Asia Pacific Meningococcal Polysaccharide Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 80. Asia Pacific Meningococcal Polysaccharide Vaccine Revenue by Region (2023-2028) & (US$ Million)
Table 81. Latin America Meningococcal Polysaccharide Vaccine Sales by Type (2017-2022) & (K Doses)
Table 82. Latin America Meningococcal Polysaccharide Vaccine Sales by Type (2023-2028) & (K Doses)
Table 83. Latin America Meningococcal Polysaccharide Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 84. Latin America Meningococcal Polysaccharide Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 85. Latin America Meningococcal Polysaccharide Vaccine Sales by Application (2017-2022) & (K Doses)
Table 86. Latin America Meningococcal Polysaccharide Vaccine Sales by Application (2023-2028) & (K Doses)
Table 87. Latin America Meningococcal Polysaccharide Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 88. Latin America Meningococcal Polysaccharide Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 89. Latin America Meningococcal Polysaccharide Vaccine Sales by Country (2017-2022) & (K Doses)
Table 90. Latin America Meningococcal Polysaccharide Vaccine Sales by Country (2023-2028) & (K Doses)
Table 91. Latin America Meningococcal Polysaccharide Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 92. Latin America Meningococcal Polysaccharide Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 93. Middle East and Africa Meningococcal Polysaccharide Vaccine Sales by Type (2017-2022) & (K Doses)
Table 94. Middle East and Africa Meningococcal Polysaccharide Vaccine Sales by Type (2023-2028) & (K Doses)
Table 95. Middle East and Africa Meningococcal Polysaccharide Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 96. Middle East and Africa Meningococcal Polysaccharide Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Meningococcal Polysaccharide Vaccine Sales by Application (2017-2022) & (K Doses)
Table 98. Middle East and Africa Meningococcal Polysaccharide Vaccine Sales by Application (2023-2028) & (K Doses)
Table 99. Middle East and Africa Meningococcal Polysaccharide Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Meningococcal Polysaccharide Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Meningococcal Polysaccharide Vaccine Sales by Country (2017-2022) & (K Doses)
Table 102. Middle East and Africa Meningococcal Polysaccharide Vaccine Sales by Country (2023-2028) & (K Doses)
Table 103. Middle East and Africa Meningococcal Polysaccharide Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Meningococcal Polysaccharide Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 105. Sanofi Corporation Information
Table 106. Sanofi Description and Major Businesses
Table 107. Sanofi Meningococcal Polysaccharide Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2017-2022)
Table 108. Sanofi Meningococcal Polysaccharide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 109. Sanofi Recent Developments
Table 110. Bio-Med Corporation Information
Table 111. Bio-Med Description and Major Businesses
Table 112. Bio-Med Meningococcal Polysaccharide Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2017-2022)
Table 113. Bio-Med Meningococcal Polysaccharide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. Bio-Med Recent Developments
Table 115. CanSinoBIO Corporation Information
Table 116. CanSinoBIO Description and Major Businesses
Table 117. CanSinoBIO Meningococcal Polysaccharide Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2017-2022)
Table 118. CanSinoBIO Meningococcal Polysaccharide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. CanSinoBIO Recent Developments
Table 120. Walvax Biotechnology Corporation Information
Table 121. Walvax Biotechnology Description and Major Businesses
Table 122. Walvax Biotechnology Meningococcal Polysaccharide Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2017-2022)
Table 123. Walvax Biotechnology Meningococcal Polysaccharide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. Walvax Biotechnology Recent Developments
Table 125. Chongqing Zhifei Biological Corporation Information
Table 126. Chongqing Zhifei Biological Description and Major Businesses
Table 127. Chongqing Zhifei Biological Meningococcal Polysaccharide Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2017-2022)
Table 128. Chongqing Zhifei Biological Meningococcal Polysaccharide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 129. Chongqing Zhifei Biological Recent Developments
Table 130. Chengdu Kanghua Biological Products Corporation Information
Table 131. Chengdu Kanghua Biological Products Description and Major Businesses
Table 132. Chengdu Kanghua Biological Products Meningococcal Polysaccharide Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2017-2022)
Table 133. Chengdu Kanghua Biological Products Meningococcal Polysaccharide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 134. Chengdu Kanghua Biological Products Recent Developments
Table 135. Changsheng Biotechnology Corporation Information
Table 136. Changsheng Biotechnology Description and Major Businesses
Table 137. Changsheng Biotechnology Meningococcal Polysaccharide Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2017-2022)
Table 138. Changsheng Biotechnology Meningococcal Polysaccharide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 139. Changsheng Biotechnology Recent Developments
Table 140. CanSinoBIO Corporation Information
Table 141. CanSinoBIO Description and Major Businesses
Table 142. CanSinoBIO Meningococcal Polysaccharide Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2017-2022)
Table 143. CanSinoBIO Meningococcal Polysaccharide Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 144. CanSinoBIO Recent Developments
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Meningococcal Polysaccharide Vaccine Distributors List
Table 148. Meningococcal Polysaccharide Vaccine Customers List
Table 149. Meningococcal Polysaccharide Vaccine Market Trends
Table 150. Meningococcal Polysaccharide Vaccine Market Drivers
Table 151. Meningococcal Polysaccharide Vaccine Market Challenges
Table 152. Meningococcal Polysaccharide Vaccine Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Meningococcal Polysaccharide Vaccine Product Picture
Figure 3. Global Meningococcal Polysaccharide Vaccine Market Share by Type in 2021 & 2028
Figure 3. Polysaccharide Meningtitis AC Product Picture
Figure 4. Meningitis ACYW Product Picture
Figure 5. Global Meningococcal Polysaccharide Vaccine Market Share by Application in 2021 & 2028
Figure 6. 6 Months-15Year
Figure 7. over 3 Year
Figure 8. over 2 Year
Figure 9. over 3 Months
Figure 10. Meningococcal Polysaccharide Vaccine Report Years Considered
Figure 11. Global Meningococcal Polysaccharide Vaccine Sales 2017-2028 (K Doses)
Figure 12. Global Meningococcal Polysaccharide Vaccine Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Meningococcal Polysaccharide Vaccine Revenue 2017-2028 (US$ Million)
Figure 14. Global Meningococcal Polysaccharide Vaccine Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 15. Global Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2017-2022)
Figure 16. Global Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2023-2028)
Figure 17. North America Meningococcal Polysaccharide Vaccine Sales YoY (2017-2028) & (K Doses)
Figure 18. North America Meningococcal Polysaccharide Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Europe Meningococcal Polysaccharide Vaccine Sales YoY (2017-2028) & (K Doses)
Figure 20. Europe Meningococcal Polysaccharide Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Asia-Pacific Meningococcal Polysaccharide Vaccine Sales YoY (2017-2028) & (K Doses)
Figure 22. Asia-Pacific Meningococcal Polysaccharide Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Latin America Meningococcal Polysaccharide Vaccine Sales YoY (2017-2028) & (K Doses)
Figure 24. Latin America Meningococcal Polysaccharide Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Middle East & Africa Meningococcal Polysaccharide Vaccine Sales YoY (2017-2028) & (K Doses)
Figure 26. Middle East & Africa Meningococcal Polysaccharide Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 27. The Meningococcal Polysaccharide Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 28. The Top 5 and 10 Largest Manufacturers of Meningococcal Polysaccharide Vaccine in the World: Market Share by Meningococcal Polysaccharide Vaccine Revenue in 2021
Figure 29. Global Meningococcal Polysaccharide Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 30. Global Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2017-2028)
Figure 31. Global Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2017-2028)
Figure 32. Global Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2017-2028)
Figure 33. Global Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2017-2028)
Figure 34. North America Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2017-2028)
Figure 35. North America Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2017-2028)
Figure 36. North America Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2017-2028)
Figure 37. North America Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2017-2028)
Figure 38. North America Meningococcal Polysaccharide Vaccine Sales Share by Country (2017-2028)
Figure 39. North America Meningococcal Polysaccharide Vaccine Revenue Share by Country (2017-2028)
Figure 40. United States Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 41. Canada Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 42. Europe Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2017-2028)
Figure 43. Europe Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2017-2028)
Figure 44. Europe Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2017-2028)
Figure 45. Europe Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2017-2028)
Figure 46. Europe Meningococcal Polysaccharide Vaccine Sales Share by Country (2017-2028)
Figure 47. Europe Meningococcal Polysaccharide Vaccine Revenue Share by Country (2017-2028)
Figure 48. Germany Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 49. France Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 50. U.K. Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 51. Italy Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 52. Russia Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 53. Asia Pacific Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2017-2028)
Figure 54. Asia Pacific Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2017-2028)
Figure 55. Asia Pacific Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2017-2028)
Figure 56. Asia Pacific Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2017-2028)
Figure 57. Asia Pacific Meningococcal Polysaccharide Vaccine Sales Share by Region (2017-2028)
Figure 58. Asia Pacific Meningococcal Polysaccharide Vaccine Revenue Share by Region (2017-2028)
Figure 59. China Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 60. Japan Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 61. South Korea Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 62. India Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 63. Australia Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 64. China Taiwan Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 65. Indonesia Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 66. Thailand Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 67. Malaysia Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 68. Latin America Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2017-2028)
Figure 69. Latin America Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2017-2028)
Figure 70. Latin America Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2017-2028)
Figure 71. Latin America Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2017-2028)
Figure 72. Latin America Meningococcal Polysaccharide Vaccine Sales Share by Country (2017-2028)
Figure 73. Latin America Meningococcal Polysaccharide Vaccine Revenue Share by Country (2017-2028)
Figure 74. Mexico Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 75. Brazil Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 76. Argentina Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 77. Colombia Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 78. Middle East and Africa Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2017-2028)
Figure 79. Middle East and Africa Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2017-2028)
Figure 80. Middle East and Africa Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2017-2028)
Figure 81. Middle East and Africa Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2017-2028)
Figure 82. Middle East and Africa Meningococcal Polysaccharide Vaccine Sales Share by Country (2017-2028)
Figure 83. Middle East and Africa Meningococcal Polysaccharide Vaccine Revenue Share by Country (2017-2028)
Figure 84. Turkey Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 85. Saudi Arabia Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 86. UAE Meningococcal Polysaccharide Vaccine Revenue (2017-2028) & (US$ Million)
Figure 87. Meningococcal Polysaccharide Vaccine Value Chain
Figure 88. Meningococcal Polysaccharide Vaccine Production Process
Figure 89. Channels of Distribution
Figure 90. Distributors Profiles
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed

---